In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Takeaways from roundtable discussion on Medical Affairs challenges at MAPS 2023 Global Annual Meeting
In spring 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders to better understand obstacles prohibiting their teams...